PBIO Pressure Biosciences

We are a leader in the development and sale of innovative, broadly enabling, pressure-based platform solutions for the worldwide life sciences industry. Our solutions are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus has been in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology platform) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be acceptably preserved using existing non-thermal technologies.

Company profile

Richard T. Schumacher
Fiscal year end
Former names
IRS number

PBIO stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


17 May 21
27 Jul 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 50.53K 50.53K 50.53K 50.53K 50.53K 50.53K
Cash burn (monthly) (positive/no burn) (positive/no burn) 358.37K 355.48K 412.34K 396.3K
Cash used (since last report) n/a n/a 1.39M 1.38M 1.6M 1.54M
Cash remaining n/a n/a -1.34M -1.33M -1.55M -1.49M
Runway (months of cash) n/a n/a -3.7 -3.7 -3.8 -3.8

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
28 May 21 Pollack Kevin Common Stock Other Aquire J No No 2.08 494 1.03K 21,897
28 May 21 Peterson Jeffrey N Common Stock Other Aquire J No No 2.08 925 1.92K 23,572
28 May 21 Urdea Michael S Common Stock Other Aquire J No No 2.08 487 1.01K 18,484
28 May 21 Mangiardi Vito J Common Stock Other Aquire J No No 2.08 106 220.48 12,908
28 May 21 Schumacher Richard T Common Stock Other Aquire J No No 2.08 212 440.96 37,746

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

6.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2 0 NEW
Opened positions 2 0 NEW
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 966K 0 NEW
Total shares 422.77K 0 NEW
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
LG Capital Funding 415.01K $950K NEW
Eudaimonia Partners 7.77K $16K NEW
Largest transactions
Shares Bought/sold Change
LG Capital Funding 415.01K +415.01K NEW
Eudaimonia Partners 7.77K +7.77K NEW

Financial report summary

Management Discussion
  • Revenue from the sale of products and services was $1,220,591 in the year ended December 31, 2020 compared with $1,809,993 in the year ended December 31, 2019, a 33% decrease. This decrease was primarily attributable to the negative impact that the COVID-19 pandemic had on our operations and the operations of our customers. Revenue included sales of both PBI and CS’s pressure-based products, and sales of Barofold Contract Services. Sales of instrumentation decreased in 2020 by $124,287 or 19%, from $653,630 in 2019 to $529,343 in 2020. Sales of consumables were $204,889 for the year ended December 31, 2020 compared to $298,385 for the same period in 2019, a decrease of $93,496 or 31%. Sales of Barofold Contract Services decreased from $380,800 in 2019 to $160,085 in 2020. Products, Services, and Other Revenue included $12,663 from non-cash transactions in the current year while the prior year included non-cash transactions of $59,456. Revenue from non-cash transactions was recognized based on the carrying value of the assets involved per ASC 845.
Content analysis
H.S. sophomore Avg
New words: agrochemical, bioavailability, biotherapeutic, candidate, consortium, cumulative, degree, dosing, effort, food, forgiven, formation, gently, greatly, growth, IIb, Insider, licensing, mutually, Nexity, Ohio, optimize, persist, Phase, placement, Podcast, profiled, prospective, regularly, revolution, SA, safer, safety, sensory, showcase, spanning, stage, strike, supplier, thousand, transformative, twelve, University, video, wholly
Removed: acceleration, acceptably, acquisition, Adrienne, advantage, American, annum, article, assume, ASU, BaroShear, Barozyme, benchtop, Bobby, brand, bring, CBD, CBM, CEO, citing, classification, close, combined, combining, consumer, decreased, demonstrate, Demonstration, Denese, developed, diligence, direct, distribution, DMD, Dr, enable, Engineering, era, event, Everest, extensive, featured, FFL, filing, FLL, Ghalili, hand, highlighted, identification, innovation, instrumental, Jim, journal, July, launch, launched, leading, Leaf, lieu, Louisiana, lower, Magazine, manufacturer, Marking, MD, medical, merger, Mini, Morrison, mortgage, nanoemulsification, network, newly, Nonqualified, North, offering, offset, oil, opening, optional, order, outsource, package, partner, person, PhD, planned, play, practical, processing, production, profit, profitable, promissory, proximity, rebranded, recent, recur, RedShiftBio, remained, revolutionary, role, rollout, ROU, sanitizer, scale, secure, sellout, Simplifying, skin, SkinScience, spending, SSL, standard, straight, strong, subsequently, Taunton, temporary, transition, USA, valuable, waive, Warsaw